Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
ACS Chemical Biology|December 27, 2014
Identification and further development of potent TBK1 inhibitorsAndré Richters, Debjit Basu, Julian Engel, et al.
European Journal of Haematology|May 7, 2021
Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routineNoëlle Sieg, Jan-Hendrik Naendrup, Philipp Gödel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2012
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variantsJohannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, et al.
Blood Advances|July 11, 2025
Sequential BCMA CAR-T Cell Therapy in Refractory Multiple MyelomaTim Richardson, Udo Holtick, Jan Hendrik Frenking, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
ALK mutations conferring differential resistance to structurally diverse ALK inhibitorsJohannes M Heuckmann, Michael Hölzel, Martin L Sos, et al.
European Journal of Haematology|January 28, 2022
Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphomaClaus Moritz Graef, Philipp Gödel, Philipp Falderbaum, et al.
Molecular Cancer|June 26, 2023
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturingHyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, et al.
European Journal of Haematology|February 19, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCRJan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, et al.
Blood Advances|January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 TrialHyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
Blood|November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNAJan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Pageof 2